Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + Pola-R-CHP in Newly-diagnosed DLBCL
NCT07371923Phase 2Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Nov 2025
- Primary completion
- Feb 2028
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Beijing Tongren Hospital. Started Nov 2025; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07371923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07371923.